

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/023,584	Rosen et al.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Gary L. Kunz	1647	

**All Participants:**

**Status of Application:** 041

(1) Gary L. Kunz.

(3) \_\_\_\_\_.

(2) Melissa Pytel.

(4) \_\_\_\_\_.

**Date of Interview:** 12 April 2004

**Time:** 10:30

**Type of Interview:**

- ☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No

If Yes, provide a brief description:

**Part I.**

Rejection(s) discussed:

*None*

Claims discussed:

*all pending claims 1 - 110*

Prior art documents discussed:

*None*

**Part II.**

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

*See Continuation Sheet*

**Part III.**

- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

Gary L. Kunz  
(Examiner/SPE Signature)

\_\_\_\_\_  
(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Ms. Pytel requested that in the restriction mailed 7/24/03 Group I (claims 1-19 and 22-50) be recombined with Group III (claims 52-66, 69-89 and 97-110) since these claims are all directed to antibodies or binding fragments thereof of VEGF-2. Additionally, Ms. Pytel requested that the restriction among the various fragments of VEGF-2 be withdrawn. Upon further consideration of the restriction requirement mailed 7/24/03, Groups I and III will be recombined. Additionally, the restriction requirement among the fragments of VEGF-2 will be withdrawn.